TRxADE HEALTH (DB:4e+40) - Aktienkurs, Nachrichten und Analyse

4e+40 Aktienübersicht

Operates as a health services information technology (IT) company in the United States.

4e+40 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 49.8% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung (€9M)

Negatives Eigenkapital

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

+ 1 mehr Risiko

TRxADE HEALTH, Inc. Wettbewerber

ifa systems

XTRA:IS8

€7.3m

ifa systems

HMSE:IS8

€7.4m

DocCheck

XTRA:AJ91

€43.4m

MeVis Medical Solutions

XTRA:M3V

€48.4m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für TRxADE HEALTH
Historische Aktienkurse
Aktueller Aktienkurs	US$6.86
52-Wochen-Hoch	US$20.01
52-Wochen-Tief	US$0.0015
Beta	1.9
11 Monat Veränderung	0%
3 Monate Veränderung	70.70%
1 Jahr Veränderung	-65.69%
33 Jahre Veränderung	-88.95%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-90.85%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	4e+40	DE Healthcare Services	DE Markt
7D	0%	-1.5%	0.4%
1Y	-65.7%	-25.0%	3.9%

Rendite im Vergleich zur Industrie: 4E40 unter dem Niveau der Branche German Healthcare Services, die im vergangenen Jahr eine Rendite von -24.9% erzielte.

Rendite vs. Markt: 4E40 hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 5.2 erzielte.

Preisvolatilität

Is 4e+40's price volatile compared to industry and market?
4e+40 volatility
4e+40 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	4.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.5%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: 4E40Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von 4E40 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2010	34	Suren Ajjarapu	www.trxadehealth.com

TRxADE HEALTH, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von TRxADE HEALTH im Vergleich zum Marktanteil des Unternehmens?
4e+40 grundlegende Statistiken
Marktanteil	€8.74m
Gewinn(TTM)	-€3.49m
Umsatz(TTM)	€8.83m

1.0x

Kurs-Umsatz-Verhältnis

-2.5x

Kurs-Gewinn-Verhältnis

Ist 4e+40 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
4e+40 Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$9.43m
Kosten der Einnahmen	US$4.16m
Bruttogewinn	US$5.27m
Sonstige Ausgaben	US$9.00m
Umsatz	-US$3.73m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.99
Bruttomarge	55.91%
Nettogewinnspanne	-39.55%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich 4e+40 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

4e+40 Aktienübersicht

Belohnungen

Risikoanalyse

TRxADE HEALTH, Inc. Wettbewerber

XTRA:IS8

€7.3m

HMSE:IS8

€7.4m

XTRA:AJ91

€43.4m

XTRA:M3V

€48.4m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

Recent updates

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

TRxADE HEALTH, Inc.'s Grundlagenzusammenfassung

1.0x

-2.5x

Erträge &amp; Einnahmen

Erträge & Einnahmen